Our Team

1 2 > >>

Martin Godbout

Martin Godbout, O.C., PhD

Chair of the Board

Following a brief academic career at Université Laval in the early 90s, Martin Godbout was named President and General Manager of Société Innovatech Québec. In 1997, he pursued his career in the biopharmaceutical venture capital sector as Senior Vice President of BioCapital. In May 2000, he became the founding President and CEO of Genome Canada, which he led for nearly 10 years.


Officer of the Order of Canada, Mr. Godbout is currently Chair of the Board of AmorChem-1, BioContact, BIOQuebec and Genome Quebec. He is also an independent Board member of the following organizations: AngioChem, Fonds de recherche du Québec - Santé, P3G, Ataxia Charlevoix-Saguenay Fondation, Leucodystrophies Fondation and Baie-Saint-Paul Hospital Fondation.


Mr. Godbout holds a PhD in Physiology and Molecular Endocrinology from Université Laval and completed a postdoctoral training in neuromolecular biology at the Scripps Research Institute, in San Diego. In 2016, he was named Grand Diplômé from Université Laval.

Marie-Josée Blais

Marie-Josée Blais


Assistant Deputy Minister, ministère de l'Économie, de la Science et de l'Innovation

Isabelle Bouffard

Isabelle Bouffard, BSc

Director, Direction recherches et politiques agricoles
Union des producteurs agricoles

Isabelle Bouffard holds a Bachelor of Agricultural Economics from McGill University. Since 2005, she has worked for the Research and Agricultural Policy department of the Union des producteurs agricoles (UPA). In 2016, she was appointed director of the department.


Prior to this, she worked as economic advisor and subsequently as manager of the economics and commerce team. Over the years, she has coordinated efforts in a variety of areas, including commerce, economics, energy and municipal taxation pertaining to agriculture. In this capacity, she has participated in the work of many provincial and national committees.

Me Jean Brunet

Me Jean Brunet

Secretary of the Board

Managing Partner of Stein Monast L.L.P.


Jean Brunet specializes in corporate and commercial law, including the negotiation and drafting of business purchase and sales agreements, mergers, corporate reorganizations and shareholders’ agreements. Mr. Brunet also practises intellectual property law, including negotiating and drafting research contracts, distribution agreements, and licence and technology transfer agreements, mainly in the sectors of pharmaceuticals, genomics, proteomics, bioinformatics and biotechnology.


In addition, Mr. Brunet acts as legal counsel and corporate secretary for various companies, particularly in the areas of biotechnology, genomics and proteomics, including active involvement on the boards of Genome Canada and Génome Québec. His duties include advising these companies on corporate governance policies and compliance matters. Mr. Brunet is one of the founders and directors of BioContact, an annual biotechnology symposium.

Daniel Coderre

Daniel Coderre, PhD

President and CEO

A certified corporate director (ASC - Administrateur de sociétés certifié) Daniel Coderre has a proven track record in public administration. He served as Rector of the Institut national de la recherche scientifique (INRS) since 2009, where he acquired solid expertise in public administration and built a wide network of partners. Mr. Coderre holds a doctorate in biology from the Université de Sherbrooke. He began his career in 1982 as a biology professor at UQAM, where he supervised 85 masters and doctoral students and published nearly 100 scientific publications. He also served as Dean of the Faculty of Science and Vice-Rector of Research before being appointed Vice-President of Academic Affairs and Research from 2004 to 2009 and in 2009, as its Interim President. He has held positions on close to twenty committees, boards of directors, scientific, government and international committees and various commissions on science, technology and innovation. 

Hélène Desmarais

Hélène Desmarais, C.M., LL.D.

CEO and Chair of the Board of Administration, Centre d'entreprises et d'innovation de Montréal


Founder, CEO and Chair of the Board of Administration of the Centre d'entreprises et d'innovation de Montréal (CEIM) since 1996, Ms. Hélène Desmarais holds a Bachelor of Business Administration in finance from HEC Montréal. CEIM is a business incubator, with an emphasis on startups as well as the development of innovative IT, multimedia, industrial technology and biotech companies. CEIM supports the emergence of viable, innovative and successful companies from those sectors which are an economic priority for the Greater Metropolitan Area of Montréal and the province of Québec.


 Ms. Desmarais is founder and Chair of the Board of Administration and of the Entrepreneurial Development Committee of the Société de développement économique Ville-Marie (SDEVM) since 1998. She is both Chair of the Board of Administration and of the Financial Assistance Committee of the SDEVM's Société d'Investissement Jeunesse (SIJ) Loan Guarantee Program. The primary mission of these two organisations is to promote entrepreneurship and economic development. The SDEVM primarily offers commercial loan guarantees to startup companies. The SIJ offers personal loan guarantees to young entrepreneurs under 35, who wish to start, acquire or become an associate in a Québec business.


Gestion Bio-Capital Inc. was founded in 1997 and was led by Ms. Desmarais as Chair of the Board of Administration until the sale of the fund in 2001. She was also a member of the verification and investment committees and member of the private investment evaluation committee at the time of the sale of the fund. Gestion Bio-Capital Inc. was a venture capital organisation specializing in biotech startups.


In 2003, Ms. Desmarais was appointed first female President of HEC's Board of Administration, to which she had been named in 1999. She is Co-President and founder of the International Advisory Board of HEC Montréal (1990), is chair of the University of Montreal's Faculty of Medicine Advisory Committee (2006), is chair of the advisory board of the Consultative Committee of the Hospital Centre of the Université de Montréal (CHUM) (2008), is President of the Advisory Board and member of the Board of Governors of the Conference of Montreal (International Economic Forum of the Americas, 1995), is President of the Board of Administration of The Montreal Economic Institute (2007) where she has held a seat since 2002, is Chair of the Canadian Joint Regional Committees since 2006, was President of the Board of Directors of the Board of Trade of Metropolitan Montreal. She was on the Board of Trade of Metropolitan Montreal from 2002-2009 and has sat on its Executive Committee since 2005. She has been Deputy Chair of the Montreal Symphony Orchestra and Chair and founder of its Fondation since 2008.  She chaired a commission formed by the Province of Quebec to study the healthcare industry (1997). 


Ms. Desmarais also sits on the following Boards of administrations : Garda World Security Corporation (2006); C.D. Howe Institute (2005); the Institute for Governance of Private and Public Organizations (2005); of the IRCM - The Institut de recherches cliniques de Montréal (2005), of Génome Québec (2002), of VAL-CHUM -- Société de valorisation des recherches du CHUM (2004). She is a member of the Conseil des partenaires de l'innovation (CIP), which falls under the aegis of Quebec's Ministry of Développement économique, Innovation et Exportation (2006), of the City of Montreal Economic Orientation Committee (2005), of the advisory board of Biotechnology Research Iinstitute, National Research Council of Canada (1998-2001) and of the Investment Committee, Hydro-Quebec CapiTech - Innovation Fund (2001-2004).


Recipient, Queen Elizabeth II’s Golden Jubilee Medal 2002; Order of Merit, Université de Montréal 2007; Medal of Honour, Faculty of Medicine of the Université de Montréal 2009; Doctor of Laws honoris causa, St. Francis Xavier University 2009; Order of Canada, Chancellery of Honours 2009; Prix entrepreneurship of Conseil du Patronat du Québec 2010; Grande Montréalaise (economic sector), Académie des grands montréalais and la Chambre de commerce du Montréal métropolitain 2010. 

Jean-François Ethier

Jean-François Ethier


Clinical Researcher and Assistant Professor
Department of medicine, Université de Sherbrooke

Professor Jean-François Ethier is a clinical researcher and assistant professor at the Department of Medicine of Université de Sherbrooke. He also works as a researcher at the INSERM UMRS-1138 in Paris in addition to coleading the Groupe de recherche interdisciplinaire en informatique de la santé (GRIIS.ca).

He holds a Bachelor of Internal Medicine from McGill University and a PhD in Epidemiology and Biomedical Information Science from Université Paris VI (Pierre and Marie Curie).

Pr. Ethier’s research focuses on ways to place patients at the centre of research and decision support systems (learning healthcare system). More specifically, he develops semantic interoperability frameworks between health and research systems, structures biomedical data warehouses and develops formal knowledge-based models to facilitate the uniform access to clinical, genomics, administrative and quantified self (lifelogging) data. 

Marc LePage

Marc LePage


President and CEO, Genome Canada


Marc LePage was appointed President and CEO of Genome Canada December 2015. Before this, he served as President and CEO of Génome Québec since December 2011, where he led a major increase in research activity and enhanced focus on the development of genomic applications within priority sectors within the province.  

He brings a wealth of experience in the innovation sector and venture capital, in addition to a broad network of international contacts.

He is an expert in international partnerships and previously served as Special Advisor, Climate Change and Energy for the Embassy of Canada in Washington, D.C. and worked as Consul General at the Canadian Consulate in San Francisco/Silicon Valley.

Marc LePage was also one of the pioneers behind the founding of Genome Canada in 2000. During his tenure as Executive Vice-President of Corporate Development, he made a significant contribution to the development of genomics in Canada.

From 1994 to 2000, he worked as Director of Business Development for the Medical Research Council, where he was in charge of building international partnerships with the pharmaceutical industry, venture capital and foundations.

Marc LePage is a member of the Board and the Governance Committee of the Quebec Network for Personalized Health Care. He also sits on the Board of Canada World Youth.

Paul Lepage

Paul Lepage, B.Eng., MBA, Dr. h.c.

President, TELUS Health and Payment Solutions
Chair, TELUS Ventures

Paul spearheads TELUS Health’s mission to harness the power of information technologies for better health care. His mission focuses on creating and integrating digital tools to help health providers and patients capture and share information in a rapid, secure and streamlined and user-friendly manner in order to support changes to the health care system aimed at improving its efficiency and empowering patients. In his commitment to expanding TELUS Health’s position as the leading organization in healthcare IT in Canada, Paul draws on more than 30 years of experience in the health telecommunications and information technology sectors.

Before joining TELUS Health in 2009, he was the President and CEO of MediSolution Ltd., a leader in the North American IT industry. Prior to this, he held various leadership roles, including Chief Marketing Officer, Chief Operating Officer and head of Global Sales for several major technology companies. Since 2016, Paul has also managed TELUS Ventures, the venture capital arm of TELUS. The branch specializes in strategic investments in market opportunities whose innovations have the potential to accelerate the growth of TELUS, particularly in the area of health.

Paul has a Master of Business Administration from Concordia University and a Bachelor of Engineering from École Polytechnique de Montréal. He serves on the board of directors for Montréal InVivo and TOHealth!as well as on the advisory board of Edmonton: Canada’s Health City in Alberta. He previously sat on the board of directors of Get Real Health in the United States, the Quebec Technology Association (QTA), IBWave, Nova Expertise Solutions, Medisolution and Blue Streak Technology, as well as serving on the Montreal Community Board of TELUS. Paul has also leveraged his expertise on committees for organizations such as CEFRIO, the Sandbox Project, the Ivey Centre for Health Innovation and the Juvenile Diabetes Research Foundation, where he also acted as honorary president and national campaign manager for several years.  He has received the ICD.D certification granted by the Institute of Corporate Directors.

Sylvain Moineau

Sylvain Moineau, PhD, FRSC

Full Professor
Département de biochimie, de microbiologie et de bio-informatique
Université Laval

Professor Sylvain Moineau completed a Bachelor of Microbiology at Université Laval in 1987. He pursued his academic career at the same university and, in 1993, earned a PhD in Food Science. During his PhD, he also spent 18 months at North Carolina State University. He then pursued industrial postdoctoral work with Unilever, the Florida-based multinational.


In 1996, he returned to Université Laval as Assistant Professor in microbiology, where his research team studies the biology of phages and phage-resistance mechanisms, including work on CRISPR-Cas systems. In 2005, he earned his full professorship and, since 2011, he holds the Canada Research Chair in Bacteriophages.


Since 2002, he has also served as the curator of the Félix d’Hérelle Reference Centre for Bacterial Viruses, the world’s largest collection of phages (www.phage.ulaval.ca


Over the years, Professor Moineau has won many teaching and research awards. In 2017, for example, he was presented with the John C. Polanyi Award by the NSERC. The award honours research done in Canada that has led to an outstanding advance in natural science or engineering. Recently, he was elected Fellow of the Academy of Science of The Royal Society of Canada. In 2016, he received the Flavelle Medal from the Royal Society of Canada for his exceptional contribution to biological science over the last decade. For three consecutive years (2014, 2015, 2016), Professor Moineau has also been on the Thomas Reuters list of the most cited researchers in the microbiology category.

1 2 > >>